Results 41 to 50 of about 12,722 (175)

Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations

Journal of the International AIDS Society, Volume 29, Issue S2, July 2026.
ABSTRACT Introduction Clinical trials are evaluating the efficacy of serogroup B meningococcal (MenB) outer membrane vesicle (OMV) vaccines in preventing gonorrhoea. We assessed the global epidemiology of gonorrhoea and MenB invasive meningococcal disease (IMD) and reviewed national MenB‐OMV vaccination policies to inform potential use of these ...
Sami L. Gottlieb, Jane Rowley, Nuria Balibrea, Dominique A. Caugant, Ray Borrow, Antoine Durupt, Helen S. Marshall, Maeve B. Mello, Marco Aurelio Sáfadi, Marie‐Pierre Preziosi   +9 more
wiley   +1 more source

Meningococcal meningitis C in Tamil Nadu, public health perspectives

Journal of Family Medicine and Primary Care, 2014
Meningococcal meningitis has rarely been reported in Tamil Nadu. We report here two children diagnosed with meningococcal meningitis in Vellore, Tamil Nadu, on May 2014. The causative strain was Neisseria meningitidis serotype C.
Kirubah Vasandhi David, Ruby Angeline Pricilla, Beeson Thomas   +2 more
doaj   +1 more source

Advancing tele‐physiology: A chest patch solution for continuous, non‐invasive remote monitoring in a hypoxic environment

Experimental Physiology, Volume 111, Issue 7, Page 3280-3293, 1 July 2026.
Abstract Skin‐mounted sensors are thin, flexible and lightweight electronic devices that enable monitoring of multiple physiological parameters. The aim of this study was to provide pilot evidence for possible utilization of a sensorized patch for capturing the bodily response to hypoxia. The subsequent phases of the study comprised a case report and a
Danilo Bondi, Ferdinando Calcagno, Elisa Fioraso, Camillo Di Giulio, Federico Schena, Anna Pedrinolla   +5 more
wiley   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

The attitudes, behaviors, and knowledge of healthcare professionals towards the diagnosis, treatment, and prevention of bacterial meningitis in Turkey

Human Vaccines & Immunotherapeutics, 2019
Introduction: Bacterial meningitis is one of the leading causes of morbidity and mortality among children and adults. Better understanding of the seroepidemiology of meningitis is critical for both the selection and implementation of an effective ...
Meltem Dinleyici, Merve Iseri Nepesov, Oguz Resat Sipahi, Kursat Bora Carman, Omer Kilic, Ener Cagri Dinleyici   +5 more
doaj   +1 more source

EPIDEMIOLOGICAL CHARACTERIZATION OF REPORTED CASES OF MENINGOCOCCAL DISEASE IN THE CITY OF SÃO PAULO, BRAZIL, BETWEEN 2019 AND 2025

Brazilian Journal of Infectious Diseases
Introduction: Meningitis is a communicable infectious disease with a significant disease burden and possible unfavorable outcomes. In this context, the World Health Organization (WHO) and the Pan American Health Organization (PAHO) developed the roadmap “
Nathália Amaro Schmidt, Ana Freitas Ribeiro   +1 more
doaj   +1 more source

Meningococcal Vaccines: Current Status and Emerging Strategies

Vaccines, 2018
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world.
Pumtiwitt C. McCarthy, Abeer Sharyan, Laleh Sheikhi Moghaddam   +2 more
doaj   +1 more source

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign. [PDF]

PLoS ONE, 2017
Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign.
Alpha Oumar Diallo, Heidi M Soeters, Issaka Yameogo, Guetawendé Sawadogo, Flavien Aké, Clément Lingani, Xin Wang, Andre Bita, Amadou Fall, Lassana Sangaré, Rasmata Ouédraogo-Traoré, Isaïe Medah, Brice Bicaba, Ryan T Novak, MenAfriNet Consortium   +14 more
doaj   +1 more source

Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond

Human Vaccines & Immunotherapeutics
Wide use of the groundbreaking vaccine MenAfriVac® has eliminated serogroup A meningococcal meningitis in the African meningitis belt and paved the way for elimination of all meningococcal disease outbreaks with the development, licensure, and ...
Mark R. Alderson, Katie Regan, Lionel Martellet, Nancy Hosken, Prasad S. Kulkarni, Sambhaji S. Pisal, F. Marc LaForce, Rajeev M. Dhere   +7 more
doaj   +1 more source

Trends in Meningitis Burden and Projections to 2040: A Secondary Analysis of the Global Burden of Disease Study 2023

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Meningitis remains a global health challenge, characterized by substantial regional and etiologic disparities. This study aimed to analyze recent trends, forecast future burden, and examine the influence of development status on meningitis outcomes.
Mehdi Azizmohammad Looha, Ali Saberi Shahrbabaki, Fatemeh Masaebi, Mahmoud Zamani, Farid Zayeri   +4 more
wiley   +1 more source